Laurus Labs Ltd - Share Price
LAURUSLABS
Laurus Labs LtdFinancials
Laurus Labs LtdNews & Updates
Laurus Labs subsidiary incorporates Laurus Ingredients; stock gains 1%
Jan 12,2021 10:02 AM
Laurus Synthesis has incorporated wholly-owned subsidiary with effect from January 9. Laurus Ingredients shall be a stepdown subsi
Meeting Type
Meeting Date
| Resolution Type | Description Of Resolution | IiAS Recommendation |
|---|
Peer Comparison
| Name | LTP | PE | Mar Cap | NP Qtr | Div. Yld | Sales Qtr | BV |
|---|---|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Ltd | 2,592.35 | 0.00 | 36,054.98 | 32.52 | 0.23 | 2,414.45 | 275.13 |
| Laurus Labs Ltd | 370.05 | 33.80 | 19,840.87 | 237.59 | 0.13 | 1,127.30 | 41.32 |
| Dr Lal Pathlabs Ltd | 2,295.45 | 97.98 | 19,117.23 | 79.90 | 0.52 | 404.30 | 136.20 |
| Fortis Healthcare Ltd | 166.35 | 386.05 | 12,532.31 | 4.15 | 0.00 | 153.13 | 117.90 |
| Metropolis Healthcare Ltd | 2,163.30 | 87.01 | 11,059.51 | 52.36 | 0.37 | 242.55 | 115.55 |
Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in Cr.
Laurus Labs LtdSummary & Reports
Laurus Labs is a leading research and development (R&D) driven pharmaceutical company in India, with a leadership position in generic active pharmaceutical ingredients (APIs) for select, high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology. The company also manufactures APIs in oncology and other therapeutic areas, such as anti-asthma, ophthalmology, antidiabetics, cardiovascular, proton pump inhibitors (P... More
Registered Office
Plot No 21 Jawaharlal Nehru,Pharma City Parawada,Visakhapatnam, Andhra Pradesh,531021
Tell. : +91-891-3061222
Website : http://www.lauruslabs.com
Email : secretarial@lauruslabs.com
Registrar Office
Karvy Selenium Tow-B, Nanakramguda, Hyderabad-500032 INDIA
Tell. : +91-40-67162222
Website : www.kfintech.com
Email : einward.ris@kfintech.com
Reports by laurus-labs-ltd-share-price
Latest Release by laurus-labs-ltd-share-price
Result Express
Laurus Labs Ltd's Q3FY19 consolidated net profit declines 48.9% yoy to Rs17.82cr : Misses Estimates
Jan 16, 2021 12:19 AM
The company’s consolidated revenue stood at Rs529.46cr, up 10.55% yoy but down 10% qoq.
Shareholding Snapshot
Loading ...
| Sep - 2020 | |
|---|---|
| Promoter | - |
| Foreign | 0.00% |
| Indian | 32.12% |
| Total Promoter | 32.12% |
| Non Promoter | - |
| Institutions | 27.08% |
| Non-Institutions | 40.79% |
| Total Non-Promoter | 67.88% |
| Custodian | 0.00% |
| Total | 100% |
Corporate Action
Purpose
Dividend
Annc. Date
29 Oct 2020
Effective. Date
10 Nov 2020
Divi. Type
Interim
Divi.(%)
40
Divi. Amt.
0.8
The Board of Directors of the Company in their meeting held on October 29, 2020 have approved for th... More
Purpose
Board Meeting
Exp. Date
29 Oct 2020
Annc. Date
19 Oct 2020
Laurus Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is schedul... More
Purpose
Split
Annc. Date
30 Apr 2020
Old FV
New FV
2
Ex-Split Date
29 Sep 2020
Outcome of Board Meeting for April 30, 2020Trading Members of the Exchange are hereby informed that ... More
Jun 12, 2017
